A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies

NCT03191773 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Lymphoma

Interventions

COMBINATION_PRODUCT: Drugs and anti-CD19 CAR transduced T cells

Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]